Sep. 13, 2017
Study finds Sensorion’s Investigative Drug Prevented Cisplatin-Induced Hearing Loss By More Than 50 Percent
MONTPELLIER, FRANCE — French biotech firm, Sensorion, announced the upcoming publication this week in the Journal of Otology & Neurotology of a new study showing oral clinical-stage SENS-401 (the company’s investigative drug) significantly prevented cisplatin-induced hearing loss in preclinical models. Cisplatin, a commonly-used chemotherapy agent to treat various forms of cancer, causes significant levels of hearing loss in 50-60% of